⭕️Como evaluar para determinar el numero de ciclos❓correcto seguimineto mejores respuestas‼️
🇦🇷UrooncoArgentina #APCCC24 OncoAlert Advanced Prostate Cancer Consensus Conference Uromigos GU Cast | Urology podcast! silke gillessen Urooncologia.arg EAU Edu Platform UROONCO Urooncologia.arg Neeraj Agarwal, MD, FASCO Asociación Argentina de Oncología Clínica (AAOC) UroTarget

Congrant!!! Wonderful meeting!!
🇦🇷UrooncoArgentina #APCCC24 OncoAlert Advanced Prostate Cancer Consensus Conference Uromigos GU Cast | Urology podcast! silke gillessen Urooncologia.arg EAU Edu Platform UROONCO Urooncologia.arg Neeraj Agarwal, MD, FASCO Asociación Argentina de Oncología Clínica (AAOC) UroTarget

For patients who have completed 6 cycles of 177Lu-PSMA treatment and meet relevant PET criteria, the majority opinion (59%) supports re-treatment only if there was a response duration of more than 6 months.

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano…

⭕️Momento a momento compartiendo información‼️
🇦🇷 #UrooncoArgentina #APCCC24 OncoAlert Advanced Prostate Cancer Consensus Conference Uromigos GU Cast | Urology podcast! silke gillessen Urooncologia.arg EAU Edu Platform UROONCO Urooncologia.arg Neeraj Agarwal, MD, FASCO Asociación Argentina de Oncología Clínica (AAOC) UroTarget

⭕️Para pte con tratamiento previo de ARPI y Qt que cumplen criterio para realizar PET-PSMA indicaría
🎯SI #CONSESNO
🇦🇷UrooncoArgentina #APCCC24 OncoAlert Advanced Prostate Cancer Consensus Conference Uromigos GU Cast | Urology podcast! silke gillessen Dr. Tomás Soulé EAU Edu Platform UROONCO Harold Somerville

⭕️Después de 4 ciclo de 177LU-PSMA con respuesta cual es la recomendacion
🎯SI #CONSENSO
🇦🇷UrooncoArgentina #APCCC24 OncoAlert Advanced Prostate Cancer Consensus Conference Uromigos GU Cast | Urology podcast! silke gillessen Dr. Tomás Soulé EAU Edu Platform UROONCO Harold Somerville Neeraj Agarwal, MD, FASCO Asociación Argentina de Oncología Clínica (AAOC) UroTarget

Cardiac evaluation is necessary before starting ARPIs. When we talk about ProstateCa, holistic care is must! #APCCC2024

The majority of responses indicate a preference for both germline and somatic genetic testing in patients with metastatic castration-resistant prostate cancer (mCRPC), which is done regardless of somatic findings.

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert…

⭕️Uno de lo momentos de mayor impacto para iniciar un nuevo modulo‼️ #Bailando
🇦🇷UrooncoArgentina #APCCC24 OncoAlert Advanced Prostate Cancer Consensus Conference Uromigos GU Cast | Urology podcast! silke gillessen Dr. Tomás Soulé EAU Edu Platform UROONCO Harold Somerville Neeraj Agarwal, MD, FASCO Asociación Argentina de Oncología Clínica (AAOC) UroTarget

⭕️Gran pausa para bailar jajajajaj...‼️ igual a la imagennnn jajajajajaja exelente.
🇦🇷 #UrooncoArgentina #APCCC24 OncoAlert Advanced Prostate Cancer Consensus Conference Uromigos GU Cast | Urology podcast! silke gillessen Dr. Tomás Soulé EAU Edu Platform UROONCO Harold Somerville Neeraj Agarwal, MD, FASCO Asociación Argentina de Oncología Clínica (AAOC) UroTarget

Most respondents favor both germline and somatic testing for patients with metastatic hormone-sensitive prostate cancer (mHSPC), regardless of findings in somatic testing.

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Elena Castro Simon C…

No consensus on the necessity of genetic evaluation for high-risk localized prostate cancer among experts?

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Elena Castro Simon C Stacy Loeb, MD Nick James Christopher Sweeney, MBBS GU Cast | Urology podcast! Joaquin Mateo LARVOL…

#APCCC24 Advanced Prostate Cancer Consensus Conference 👉 How to select mCRPC pts #ProstateCancer for lutetium-177 RLT therapy ?👉excellent talk by Thomas Hope 👉select pts based on ⬆️uptake than liver, post-Rx SPECT (+conventional scans) & not PSMA-PET should be done to follow pts👇 OncoAlert PCF Science

⭕️Ligándoos alternativos al PSMA, tenemos que solucionar ahora por sitio mts🧐❓
🇦🇷 #UrooncoArgentina #APCCC24 OncoAlert Advanced Prostate Cancer Consensus Conference Uromigos GU Cast | Urology podcast! silke gillessen Harold Somerville EAU Edu Platform UROONCO Dr. Tomás Soulé Neeraj Agarwal, MD, FASCO Asociación Argentina de Oncología Clínica (AAOC) UroTarget

⭕️Cual es la mejor secuencia de trtatamiento con tantas opciones 🧩 #evidencia #acceso
🇦🇷UrooncoArgentina #APCCC24 OncoAlert Advanced Prostate Cancer Consensus Conference Uromigos GU Cast | Urology podcast! silke gillessen Dr. Tomás Soulé EAU Edu Platform UROONCO Harold Somerville Neeraj Agarwal, MD, FASCO Asociación Argentina de Oncología Clínica (AAOC) UroTarget

Important results. It doesn’t make sense the use of PARPi in non HRD patients

#APCCC2024 Advanced Prostate Cancer Consensus Conference 👉 Nick James presents The Lancet commission on #prostatecancer 👉incidence and mortality set to rise sharply, in low- & middle income countries👉key messages on treatment and final take home message👇OncoAlert PCF Science UroToday.com…

#APCCC24 Advanced Prostate Cancer Consensus Conference 👉 Andrew Armstrong ‘s comprehensive talk on emerging Rx options in neuro-endocrine #prostatecancer 👉Lurbinectedin, CXCR2i, DLL3i and other potential Rx strategies👇OncoAlert PCF Science UroToday.com

Check out our APCCC podcasts with Jason Efstathiou and Piet Ost discuss the data for and against adjuvant radiotherapy. podcasters.spotify.com/pod/show/the-u…

👉Pacientes resistentes a la castración ¿Qué hacemos con ellos?

🇦🇷UrooncoArgentina #APCCC24 OncoAlert Advanced Prostate Cancer Consensus Conference GU Cast | Urology podcast! Juan Pablo Sade EAU Edu Platform UROONCO
Neeraj Agarwal, MD, FASCO Asociación Argentina de Oncología Clínica (AAOC) UroTarget Rodrigo Sanchez Roger